BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11264255)

  • 21. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis.
    Pascale RM; Simile MM; De Miglio MR; Muroni MR; Calvisi DF; Asara G; Casabona D; Frau M; Seddaiu MA; Feo F
    Hepatology; 2002 Jun; 35(6):1341-50. PubMed ID: 12029619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth.
    Goukassian DA; Kishore R; Krasinski K; Dolan C; Luedemann C; Yoon YS; Kearney M; Hanley A; Ma H; Asahara T; Isner JM; Losordo DW
    Circ Res; 2003 Jul; 93(2):162-9. PubMed ID: 12829616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the G1/S transition phase in mesangial cells by E2F1.
    Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
    Kidney Int; 1999 Oct; 56(4):1238-41. PubMed ID: 10504464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.
    Chen D; Krasinski K; Sylvester A; Chen J; Nisen PD; Andrés V
    J Clin Invest; 1997 May; 99(10):2334-41. PubMed ID: 9153274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity.
    Turley JM; Ruscetti FW; Kim SJ; Fu T; Gou FV; Birchenall-Roberts MC
    Cancer Res; 1997 Jul; 57(13):2668-75. PubMed ID: 9205075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
    Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases.
    Wang S; Nath N; Minden A; Chellappan S
    EMBO J; 1999 Mar; 18(6):1559-70. PubMed ID: 10075927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
    Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
    Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells.
    Zhu WY; Jones CS; Kiss A; Matsukuma K; Amin S; De Luca LM
    Exp Cell Res; 1997 Aug; 234(2):293-9. PubMed ID: 9260897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deregulation of specific E2F complexes by the v-mos oncogene.
    Afshari CA; Rhodes N; Paules RS; Mudryj M
    Oncogene; 1997 Jun; 14(25):3029-38. PubMed ID: 9223666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells.
    Sala A; Nicolaides NC; Engelhard A; Bellon T; Lawe DC; Arnold A; Graña X; Giordano A; Calabretta B
    Cancer Res; 1994 Mar; 54(6):1402-6. PubMed ID: 8137237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
    Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
    Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.
    Alevizopoulos K; Vlach J; Hennecke S; Amati B
    EMBO J; 1997 Sep; 16(17):5322-33. PubMed ID: 9311992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
    Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
    Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Kiyono T; Fleck E; Van Herle A; Graf K; Law RE
    Eur J Pharmacol; 2003 Feb; 462(1-3):15-23. PubMed ID: 12591091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
    Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
    DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter.
    Spitkovsky D; Schulze A; Boye B; Jansen-Dürr P
    Cell Growth Differ; 1997 Jun; 8(6):699-710. PubMed ID: 9186003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorylation of E2F-1 by cyclin A-cdk2.
    Kitagawa M; Higashi H; Suzuki-Takahashi I; Segawa K; Hanks SK; Taya Y; Nishimura S; Okuyama A
    Oncogene; 1995 Jan; 10(2):229-36. PubMed ID: 7838523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
    Schwarz JK; Bassing CH; Kovesdi I; Datto MB; Blazing M; George S; Wang XF; Nevins JR
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):483-7. PubMed ID: 7831315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.